A Mount Sinai-led study on inter-atrial shunts reveals significantly divergent health outcomes for heart failure patients, depending on whether their left ventricular ejection fraction is reduced or preserved.

Summary: The RELIEVE-HF study led by Mount Sinai revealed that inter-atrial shunts may benefit heart failure patients with reduced left ventricular ejection fraction (LVEF) by decreasing hospitalizations and adverse cardiovascular events. However, these devices posed increased risks, including higher mortality and hospitalization rates, for patients with preserved LVEF. The trial, conducted across 101 sites in 11 countries, involved 508 patients and marked the first study to differentiate impacts of shunts based on LVEF categories. The findings suggest a need for cautious patient selection in the deployment of these devices.

Key Takeaways:

  • The RELIEVE-HF study discovered that inter-atrial shunts helped reduce adverse cardiovascular events and hospitalizations by 45% in heart failure patients with reduced left ventricular ejection fraction (LVEF ≤ 40%), but increased these events by 68% in patients with preserved LVEF (LVEF > 40%).
  • In patients with preserved LVEF, those treated with the shunt experienced a 224% increase in all-cause mortality and a 105% increase in heart failure hospitalizations compared to those who underwent a placebo procedure.
  • The trial included 508 symptomatic heart failure patients, randomized at 101 sites across 11 countries, with findings presented after a median follow-up of 22 months.

Inter-atrial shunts—investigational devices that create a small pathway for blood to pass from the left to the right side of the heart in order to improve heart failure symptoms and outcomes—may be beneficial to heart failure patients with reduced left ventricular ejection fraction (LVEF) but harmful or even deadly for heart failure patients with preserved LVEF, a new Mount Sinai-led study shows.  

The findings of the RELIEVE-HF trial were announced during the opening late-breaking trial session at the American College of Cardiology Scientific Sessions. This is the first study to analyze the impact of inter-atrial shunts in patients with both reduced and preserved LVEF and the first to show different outcomes in these two groups.  

“Although further studies are required to confirm our observations, the present results strongly suggests that heart failure patients with reduced LVEF may benefit from these devices,” says Gregg W. Stone, MD, one of the principal investigators of RELIEVE-HF, who presented the trial results, in a release.

“Furthermore, this study serves as a warning to cardiologists: Inter-atrial shunt treatment in heart failure patients with preserved LVEF may increase hospitalizations for heart failure and even mortality. This is especially relevant to geographies such as Europe where numerous inter-atrial shunt devices have already been approved for general use based on earlier small studies,” adds DStone, who is director of academic affairs for the Mount Sinai Health System and professor of medicine (cardiology) and population health science and policy at the Icahn School of Medicine at Mount Sinai.

Investigational Inter-Atrial Shunts

Inter-atrial shunts are small (5-10 millimeter diameter) permanent devices, placed in the heart via a minimally invasive catheter-based procedure, that connect the left and right atria. The shunt allows blood to pass from left to right to reduce high pressures in the left atrium that can cause shortness of breath and hospitalizations for heart failure.

Roughly half of all patients with heart failure have preserved LVEF, which means the left ventricle pumps out at least 50% of the normal amount of blood. In these patients, the heart’s left ventricle is too stiff to properly fill with blood. In the other type of heart failure, reduced LVEF, the heart’s left ventricle pumps out blood below normal levels with an ejection fraction of 40% or less. 

Patients with a LVEF between 40% and 50% were historically considered to have preserved ejection fraction, but now they are often classified as having “mildly reduced” LVEF.

Trial Assesses Inter-Atrial Shunts in Heart Failure Patients

In this trial, researchers randomized 508 symptomatic heart failure patients at 101 sites in 11 countries between October 2018 and October 2022. Within the study group, 205 patients had reduced LVEF (40% or less), and 303 had preserved LVEF (above 40%). Roughly half of the patients in each group got the Ventura inter-atrial shunt (made by V-Wave Medical) and the other half had a placebo procedure blinded to the patient, families, and health care providers. 

The patients were studied for up to two years after treatment, with a 22-month median follow-up.

Investigators analyzed the safety of the procedure, defined as the 30-day rate of device-related or procedure-related adverse cardiac events (all-cause death, stroke, systemic embolism, need for open cardiac surgery, or major endovascular surgical repair) in the reduced and preserved LVEF groups; heart failure hospitalizations; worsening heart failure symptoms and events at home; and improvement in quality of life.

The effectiveness of the procedure was measured from most to least important by factors that included, in order from high to low, all-cause death, cardiac transplantation or left ventricular assist device implantation, hospitalizations for heart failure, worsening heart failure symptoms requiring medical attention outside of the hospital setting, and change in quality of life from baseline as measured by the Kansas City Cardiomyopathy Questionnaire overall summary score through a maximum two-year follow-up, assessed when the last enrolled patient reached one-year follow-up after randomization.

Trial Results: Varied Efficacy Based on Heart Function

In the entire study, no adverse safety events related to the device or the procedure occurred either within 30 days or two years, demonstrating the safety of the inter-atrial shunt. There were no overall improvements in the primary effectiveness endpoint, including no changes in prognosis or quality of life, when the results were analyzed in all patients. 

However, the outcomes were dependent on whether patients had reduced or preserved LVEF: 49% of reduced-LVEF patients had adverse cardiovascular events per year after shunt treatment compared with 88.6% of those with a placebo procedure, a 45% reduction that was highly statistically significant (P<0.0001). In contrast, among patients with preserved LVEF, 60.2% had adverse cardiovascular events per year after shunt treatment compared with 35.9% in the placebo group, a 68% increase (P=0.0001).

More specifically, the cardiovascular benefits from the shunt in reduced-LVEF patients were driven by 48% fewer hospitalizations for heart failure. The worse cardiovascular outcomes in preserved-LVEF patients were linked to a 224% increase in all-cause death and a 105% increase in hospitalizations for heart failure in shunt patients.

“When we began this study we weren’t sure if the outcomes in patients with reduced and preserved LVEF would be similar. We were surprised with how different they are,” says Stone in a release. “Heart failure patients with LVEF at or under 40% have a poor prognosis and often can’t tolerate medical therapy. Inter-atrial shunt treatment may markedly improve their lives. The present results warrant the need for future studies in these patients to confirm our findings. Conversely, our results question the safety of using inter-atrial shunts in heart failure patients with LVEF above 40%.”

The RELIEVE-HF trial was funded by V-Wave Ltd., Caesarea, Israel.

Photo 81421124 | Virus © Wavebreakmedia Ltd | Dreamstime.com